IRAK2 and invasive breast carcinoma: We can envision a variety of scenarios in which the IRAK4 rs4251545 minor variant might promote BrCa risk by altering the expression or phosphorylation state of IRAK4 or its interaction with upstream adaptors (like MyD88) and/or downstream kinases (like IRAK1 and IRAK2) and E3 ubiquitin ligases (like TRAF6).